Drug intelligence / Profile preview

BAT2406

Development stage: Unknown
Lead developer: Bio-Thera Solutions
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Parenteral

Overview

BAT2406 is a proposed biosimilar to dupilumab being developed by Bio-Thera Solutions as a recombinant monoclonal antibody targeting the interleukin-4 receptor alpha subunit (IL-4Rα). By binding IL-4Rα, it blocks signaling of both IL‑4 and IL‑13, key type 2 cytokines that drive inflammatory pathways in a range of autoimmune and allergic diseases, mirroring the mechanism of the reference product Dupixent (dupilumab).[1][3][5][13] BAT2406 has received NMPA approval for clinical trials in China and is currently in phase 1 development for autoimmune disorders, with regional commercialization partnerships in Latin America.[10][13][14][15]

Other names: dupilumab biosimilar BAT2406

Targets

IL4R (Interleukin-4 receptor alpha subunit)

Beyond the preview

Go deeper on BAT2406.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAT2406.

Explore the full profile